We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 06, 2021

Long-Term Follow-Up of Sorafenib or Placebo in Patients With Newly Diagnosed AML



Additional Info

Disclosure statements are available on the authors' profiles:

Sorafenib or Placebo in Patients With Newly Diagnosed Acute Myeloid Leukaemia: Long-Term Follow-Up of the Randomized Controlled SORAML Trial
Leukemia 2021 Feb 18;[EPub Ahead of Print], C Röllig, H Serve, R Noppeney, M Hanoun, U Krug, CD Baldus, CH Brandts, V Kunzmann, H Einsele, A Krämer, C Müller-Tidow, K Schäfer-Eckart, A Neubauer, A Burchert, A Giagounidis, SW Krause, A Mackensen, W Aulitzky, R Herbst, M Hänel, N Frickhofen, J Kullmer, U Kaiser, A Kiani, H Link, T Geer, A Reichle, C Junghanß, R Repp, A Meinhardt, H Dürk, IM Klut, M Bornhäuser, M Schaich, S Parmentier, M Görner, C Thiede, M von Bonin, U Platzbecker, J Schetelig, M Kramer, WE Berdel, G Ehninger

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading